[Phase III clinical study of a new anticancer drug atofluding].

@article{Li2002PhaseIC,
  title={[Phase III clinical study of a new anticancer drug atofluding].},
  author={Qing Li and Feng-yi Feng and Jun Youl Han and Guang-jie Sui and Yan-guang Zhu and Yang Zhang and Zhen-hua Zhang and Li Li and Ping-hui Wang and Mei-zhen Zhou and Ying-Chao Zhang},
  journal={Ai zheng = Aizheng = Chinese journal of cancer},
  year={2002},
  volume={21 12},
  pages={1350-3}
}
BACKGROUND & OBJECTIVE Atofloding (ATFU) is a new derivative of 5-fluorouracil. The phase I and II clinical study have been finished. The current study was a phase III clinical trail of ATFU. The aim of this study was to evaluate the efficacy, toxicity of ATFU combination chemotherapy and compare with ftorafur (FT-207) in patients with gastric cancer, colorectal, esophageal cancer, and liver cancer. METHODS A multicenter, open randomized controlled trial was carried out. A total of 320… CONTINUE READING